Administration of an antibody against apoptosis inhibitor of macrophage prevents aortic aneurysm progression in mice.
Animals
Mice
Aortic Aneurysm
/ prevention & control
Macrophages
/ metabolism
Disease Progression
Apoptosis
/ drug effects
Disease Models, Animal
Male
Antibodies, Monoclonal
/ pharmacology
Aorta
/ pathology
Mice, Inbred C57BL
Tumor Necrosis Factor-alpha
/ metabolism
Apoptosis Regulatory Proteins
Receptors, Scavenger
Aortic aneurysm
Apoptosis inhibitor of macrophage
Inflammation
Macrophage
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
10 Jul 2024
10 Jul 2024
Historique:
received:
29
03
2024
accepted:
03
07
2024
medline:
10
7
2024
pubmed:
10
7
2024
entrez:
9
7
2024
Statut:
epublish
Résumé
Apoptosis inhibitor of macrophage (AIM) is known to induce apoptosis resistance in macrophages and to exacerbate chronic inflammation, leading to arteriosclerosis. The role of AIM in aortic aneurysm (AA) remains unknown. This study examined the effects of an anti-AIM antibody in preventing AA formation and progression. In apolipoprotein E-deficient mice, AA was induced by subcutaneous angiotensin II infusion. Mice were randomly divided into two groups: (i) AIM group; weekly anti-murine AIM monoclonal antibody injection (n = 10), and (ii) IgG group; anti-murine IgG antibody injection as control (n = 14). The AIM group, compared with the IgG group, exhibited reduced AA enlargement (aortic diameter at 4 weeks: 2.1 vs. 2.7 mm, respectively, p = 0.012); decreased loss of elastic lamellae construction; reduced expression levels of IL-6, TNF-α, and MCP-1; decreased numbers of AIM-positive cells and inflammatory M1 macrophages (AIM: 1.4 vs. 8.0%, respectively, p = 0.004; M1 macrophages: 24.5 vs. 55.7%, respectively, p = 0.017); and higher expression of caspase-3 in the aortic wall (22.8 vs. 10.5%, respectively, p = 0.019). Our results suggest that administration of an anti-AIM antibody mitigated AA progression by alleviating inflammation and promoting M1 macrophage apoptosis.
Identifiants
pubmed: 38982113
doi: 10.1038/s41598-024-66791-7
pii: 10.1038/s41598-024-66791-7
doi:
Substances chimiques
Cd5l protein, mouse
0
Antibodies, Monoclonal
0
Tumor Necrosis Factor-alpha
0
Apoptosis Regulatory Proteins
0
Receptors, Scavenger
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
15878Informations de copyright
© 2024. The Author(s).
Références
Moulakakis, K. G. et al. Open repair of thoracoabdominal aortic aneurysms in experienced centers. J. Vasc. Surg. 68, 634-645.e612. https://doi.org/10.1016/j.jvs.2018.03.410 (2018).
doi: 10.1016/j.jvs.2018.03.410
pubmed: 30037680
Daye, D. & Walker, T. G. Complications of endovascular aneurysm repair of the thoracic and abdominal aorta: Evaluation and management. Cardiovasc. Diagn. Ther. 8, S138-s156. https://doi.org/10.21037/cdt.2017.09.17 (2018).
doi: 10.21037/cdt.2017.09.17
pubmed: 29850426
pmcid: 5949591
Ulug, P., Powell, J. T., Martinez, M. A., Ballard, D. J. & Filardo, G. Surgery for small asymptomatic abdominal aortic aneurysms. Cochrane Database Syst. Rev. 7, Cd001835. https://doi.org/10.1002/14651858.CD001835.pub5 (2020).
doi: 10.1002/14651858.CD001835.pub5
pubmed: 32609382
Li, R., Liu, Y. & Jiang, J. Research advances in drug therapy for abdominal aortic aneurysms over the past five years: An updated narrative review. Int. J. Cardiol. 372, 93–100. https://doi.org/10.1016/j.ijcard.2022.11.058 (2023).
doi: 10.1016/j.ijcard.2022.11.058
pubmed: 36462700
Sprague, A. H. & Khalil, R. A. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem. Pharmacol. 78, 539–552. https://doi.org/10.1016/j.bcp.2009.04.029 (2009).
doi: 10.1016/j.bcp.2009.04.029
pubmed: 19413999
pmcid: 2730638
Dale, M. A., Ruhlman, M. K. & Baxter, B. T. Inflammatory cell phenotypes in AAAs: Their role and potential as targets for therapy. Arterioscler. Thromb. Vasc. Biol. 35, 1746–1755. https://doi.org/10.1161/atvbaha.115.305269 (2015).
doi: 10.1161/atvbaha.115.305269
pubmed: 26044582
pmcid: 4514552
Tabas, I. & Bornfeldt, K. E. Macrophage phenotype and function in different stages of atherosclerosis. Circ. Res. 118, 653–667. https://doi.org/10.1161/circresaha.115.306256 (2016).
doi: 10.1161/circresaha.115.306256
pubmed: 26892964
pmcid: 4762068
Yamawaki-Ogata, A. et al. Therapeutic potential of bone marrow-derived mesenchymal stem cells in formed aortic aneurysms of a mouse model. Eur. J. Cardiothorac. Surg. 45, e156-165. https://doi.org/10.1093/ejcts/ezu018 (2014).
doi: 10.1093/ejcts/ezu018
pubmed: 24554076
Miyazaki, T., Hirokami, Y., Matsuhashi, N., Takatsuka, H. & Naito, M. Increased susceptibility of thymocytes to apoptosis in mice lacking AIM, a novel murine macrophage-derived soluble factor belonging to the scavenger receptor cysteine-rich domain superfamily. J. Exp. Med. 189, 413–422. https://doi.org/10.1084/jem.189.2.413 (1999).
doi: 10.1084/jem.189.2.413
pubmed: 9892623
pmcid: 2192994
Haruta, I. et al. Association of AIM, a novel apoptosis inhibitory factor, with hepatitis via supporting macrophage survival and enhancing phagocytotic function of macrophages. J. Biol. Chem. 276, 22910–22914. https://doi.org/10.1074/jbc.M100324200 (2001).
doi: 10.1074/jbc.M100324200
pubmed: 11294859
Kuwata, K. et al. AIM inhibits apoptosis of T cells and NKT cells in Corynebacterium-induced granuloma formation in mice. Am. J. Pathol. 162, 837–847. https://doi.org/10.1016/s0002-9440(10)63880-1 (2003).
doi: 10.1016/s0002-9440(10)63880-1
pubmed: 12598318
pmcid: 1868086
Sanjurjo, L., Aran, G., Roher, N., Valledor, A. F. & Sarrias, M. R. AIM/CD5L: A key protein in the control of immune homeostasis and inflammatory disease. J. Leukoc. Biol. 98, 173–184. https://doi.org/10.1189/jlb.3RU0215-074R (2015).
doi: 10.1189/jlb.3RU0215-074R
pubmed: 26048980
Kurokawa, J. et al. Apoptosis inhibitor of macrophage (AIM) is required for obesity-associated recruitment of inflammatory macrophages into adipose tissue. Proc. Natl. Acad. Sci. U. S. A. 108, 12072–12077. https://doi.org/10.1073/pnas.1101841108 (2011).
doi: 10.1073/pnas.1101841108
pubmed: 21730133
pmcid: 3141977
Gao, X. et al. Therapeutic targeting of apoptosis inhibitor of macrophage/CD5L in Sepsis. Am. J. Respir. Cell. Mol. Biol. 60, 323–334. https://doi.org/10.1165/rcmb.2018-0272OC (2019).
doi: 10.1165/rcmb.2018-0272OC
pubmed: 30326743
Arai, S. et al. A role for the apoptosis inhibitory factor AIM/Spalpha/Api6 in atherosclerosis development. Cell Metab. 1, 201–213. https://doi.org/10.1016/j.cmet.2005.02.002 (2005).
doi: 10.1016/j.cmet.2005.02.002
pubmed: 16054063
Miyazaki, T., Kurokawa, J. & Arai, S. AIMing at metabolic syndrome—Towards the development of novel therapies for metabolic diseases via apoptosis inhibitor of macrophage (AIM). Circ. J. 75, 2522–2531. https://doi.org/10.1253/circj.cj-11-0891 (2011).
doi: 10.1253/circj.cj-11-0891
pubmed: 21970839
Arai, S. & Miyazaki, T. Impacts of the apoptosis inhibitor of macrophage (AIM) on obesity-associated inflammatory diseases. Semin. Immunopathol. 36, 3–12. https://doi.org/10.1007/s00281-013-0405-5 (2014).
doi: 10.1007/s00281-013-0405-5
pubmed: 24281248
Kurokawa, J. et al. Macrophage-derived AIM is endocytosed into adipocytes and decreases lipid droplets via inhibition of fatty acid synthase activity. Cell Metab. 11, 479–492. https://doi.org/10.1016/j.cmet.2010.04.013 (2010).
doi: 10.1016/j.cmet.2010.04.013
pubmed: 20519120
Haruta, I. et al. Apoptosis inhibitor expressed by macrophages tempers autoimmune colitis and the risk of colitis-based carcinogenesis in TCRalpha−/− mice. J. Clin. Immunol. 27, 549–556. https://doi.org/10.1007/s10875-007-9110-2 (2007).
doi: 10.1007/s10875-007-9110-2
pubmed: 17619226
Ono, Y. et al. The utility of apoptosis inhibitor of macrophages as a possible diagnostic marker in patients with Crohn’s disease. BMC Gastroenterol. 17, 40. https://doi.org/10.1186/s12876-017-0591-z (2017).
doi: 10.1186/s12876-017-0591-z
pubmed: 28284201
pmcid: 5346245
Irabu, H. et al. Apoptosis inhibitor of macrophage as a biomarker for disease activity in Japanese children with IgA nephropathy and Henoch–Schönlein purpura nephritis. Pediatr. Res. 89, 667–672. https://doi.org/10.1038/s41390-020-0951-1 (2021).
doi: 10.1038/s41390-020-0951-1
pubmed: 32408340
Wu, X., Li, M., Chen, T., Zhong, H. & Lai, X. Apoptosis inhibitor of macrophage/CD5L is associated with disease activity in rheumatoid arthritis. Clin. Exp. Rheumatol. 39, 58–65. https://doi.org/10.55563/clinexprheumatol/fihu4r (2021).
doi: 10.55563/clinexprheumatol/fihu4r
pubmed: 32194022
Tanoue, S. et al. Role of apoptosis inhibitor of macrophages in patients with IgG4-related disease/autoimmune pancreatitis and the clinical characteristics associated with this condition. Biomed. Rep. 17, 82. https://doi.org/10.3892/br.2022.1565 (2022).
doi: 10.3892/br.2022.1565
pubmed: 36158321
pmcid: 9468806
Mera, K. et al. Serum levels of apoptosis inhibitor of macrophage are associated with hepatic fibrosis in patients with chronic hepatitis C. BMC Gastroenterol. 14, 27. https://doi.org/10.1186/1471-230x-14-27 (2014).
doi: 10.1186/1471-230x-14-27
pubmed: 24524410
pmcid: 3937012
Aran, G. et al. CD5L is upregulated in hepatocellular carcinoma and promotes liver cancer cell proliferation and antiapoptotic responses by binding to HSPA5 (GRP78). FASEB J. 32, 3878–3891. https://doi.org/10.1096/fj.201700941RR (2018).
doi: 10.1096/fj.201700941RR
pubmed: 29465313
Kimura, H. et al. Orchestrating role of apoptosis inhibitor of macrophage in the resolution of acute lung injury. J. Immunol. 199, 3870–3882. https://doi.org/10.4049/jimmunol.1601798 (2017).
doi: 10.4049/jimmunol.1601798
pubmed: 29070674
Arai, S. & Miyazaki, T. A scavenging system against internal pathogens promoted by the circulating protein apoptosis inhibitor of macrophage (AIM). Semin. Immunopathol. 40, 567–575. https://doi.org/10.1007/s00281-018-0717-6 (2018).
doi: 10.1007/s00281-018-0717-6
pubmed: 30310974
pmcid: 6223838
Gao, X., Yan, X., Zhang, Q., Yin, Y. & Cao, J. CD5L contributes to the pathogenesis of methicillin-resistant Staphylococcus aureus-induced pneumonia. Int. Immunopharmacol. 72, 40–47. https://doi.org/10.1016/j.intimp.2019.03.057 (2019).
doi: 10.1016/j.intimp.2019.03.057
pubmed: 30959370
Nishikido, T., Oyama, J., Shiraki, A., Komoda, H. & Node, K. Deletion of apoptosis inhibitor of macrophage (AIM)/CD5L attenuates the inflammatory response and infarct size in acute myocardial infarction. J. Am. Heart Assoc. 5, e002863. https://doi.org/10.1161/jaha.115.002863 (2016).
doi: 10.1161/jaha.115.002863
pubmed: 27045005
pmcid: 4859278
Ishikawa, S. et al. Apoptosis inhibitor of macrophage depletion decreased M1 macrophage accumulation and the incidence of cardiac rupture after myocardial infarction in mice. PLoS One 12, e0187894. https://doi.org/10.1371/journal.pone.0187894 (2017).
doi: 10.1371/journal.pone.0187894
pubmed: 29121663
pmcid: 5679665
Eagleton, M. J. et al. Early increased MT1-MMP expression and late MMP-2 and MMP-9 activity during angiotensin II induced aneurysm formation. J. Surg. Res. 135, 345–351. https://doi.org/10.1016/j.jss.2006.03.026 (2006).
doi: 10.1016/j.jss.2006.03.026
pubmed: 16716358
Wang, X. & Khalil, R. A. Matrix metalloproteinases, vascular remodeling, and vascular disease. Adv. Pharmacol. 81, 241–330. https://doi.org/10.1016/bs.apha.2017.08.002 (2018).
doi: 10.1016/bs.apha.2017.08.002
pubmed: 29310800
Mattes, M. J. Biodistribution of antibodies after intraperitoneal or intravenous injection and effect of carbohydrate modifications. J. Natl. Cancer Inst. 79, 855–863 (1987).
pubmed: 2443739
Kumagai, Y. et al. Effect of systemic or intraperitoneal administration of anti-PD-1 antibody for peritoneal metastases from gastric cancer. In Vivo 36, 1126–1135. https://doi.org/10.21873/invivo.12811 (2022).
doi: 10.21873/invivo.12811
pubmed: 35478147
pmcid: 9087086
Daugherty, A., Manning, M. W. & Cassis, L. A. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J. Clin. Investig. 105, 1605–1612. https://doi.org/10.1172/JCI7818 (2000).
doi: 10.1172/JCI7818
pubmed: 10841519
pmcid: 300846
Rateri, D. L. et al. Prolonged infusion of angiotensin II in apoE(−/−) mice promotes macrophage recruitment with continued expansion of abdominal aortic aneurysm. Am. J. Pathol. 179, 1542–1548. https://doi.org/10.1016/j.ajpath.2011.05.049 (2011).
doi: 10.1016/j.ajpath.2011.05.049
pubmed: 21763672
pmcid: 3157213
Johnston, K. W. et al. Suggested standards for reporting on arterial aneurysms. Subcommittee on reporting standards for arterial aneurysms, ad hoc committee on reporting standards, society for vascular surgery and North American Chapter, international society for cardiovascular surgery. J. Vasc. Surg. 13, 452–458. https://doi.org/10.1067/mva.1991.26737 (1991).
doi: 10.1067/mva.1991.26737
pubmed: 1999868
Ashida, S. et al. Administration of anti-inflammatory M2 macrophages suppresses progression of angiotensin II-induced aortic aneurysm in mice. Sci. Rep. 13, 1380. https://doi.org/10.1038/s41598-023-27412-x (2023).
doi: 10.1038/s41598-023-27412-x
pubmed: 36697439
pmcid: 9877022